James C. Wernz - Concepedia

Author

James C. Wernz

Columbia University Irving Medical Center

Also Known As

J C Wernz, James C. Wernz, James Wernz

Publications

703

Citations

H-Index

Concepts

All Affiliations

Columbia University Irving Medical Center New York University NYU Langone Health Stanley Foundation

About

James C. Wernz is an author at Columbia University Irving Medical Center specializing in medicine, pharmacotherapy, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	337
2	Pathology	3	3	259
3	Pharmacology	3	3	50
4	Immunology	2	2	229
5	Obstetrics	2	2	40

James C. Wernz

Publications

692

Citations

H-Index

Page 1

	Year	Citations
Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast Cancer James L. Speyer, Michael D. Green, E Douglas Kramer, New England Journal of Medicine	1988	355
Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria Susan E. Krown, Craig E. Metroka, James C. Wernz Primary ImmunodeficiencyAutoimmune DiseaseImmunodeficienciesImmunologyPathology	1989	217
Carcinomatous meningitis from transitional cell carcinoma of bladder Sue Mandell, James C. Wernz, Pablo Morales, Urology UrologyCarcinomatous MeningitisGenitourinary CancerHistopathologyPathology	1985	30
Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule. Robert J. Spiegel, Ronald H. Blum, Mark Levin, PubMed 9,10-Anthracene DicarboxaldehydeMedicinal ChemistryDaily I.vMedicineSubstituted Anthracene	1982	26
Advanced ovarian cancer: Three-year results of a 6–8 month, 2-drug cisplatin-containing regimen M. Piccart, James L. Speyer, James C. Wernz, European Journal of Cancer and Clinical Oncology Advanced Ovarian CancerMedicineMetronomic TherapyGynecology2-Drug Cisplatin-containing Regimen	1987	22
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients Nicoletta Colombo, James L. Speyer, Michael R. Green, Cancer Chemotherapy and Pharmacology MedicineMetronomic TherapySevere Hematologic ToxicityGynecologyRecurrent Ovarian Cancer	1989	18
Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): A phase I study with pharmacology Howard S. Höchster, Michael Green, Leonard Liebes, Cancer Chemotherapy and Pharmacology Weekly Oral IdarubicinAntibiotic AdjuvantPharmacologyGood TolerancePharmacotherapy	1990	12
Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon. Michael David Green, James L. Speyer, Howard S. Höchster, PubMed Doxorubicin ToxicityOncologyImmunologyPharmacologyPathology	1988	12

Page 1